Key result
VKORC1 single nucleotide polymorphisms were strongly associated with the average weekly warfarin dose required to achieve target INR (P<0.0001), with mean doses ranging from 27 to 47 mg by genotype.
Why the study?
Do VKORC1 and CYP2C9 polymorphisms affect the average weekly warfarin dose required to maintain target anticoagulation in European-American patients?
Observational (n=93)
No
Do VKORC1 and CYP2C9 polymorphisms affect the average weekly warfarin dose required to maintain target anticoagulation in European-American patients?
p-value: p=<0.0001
VKORC1 polymorphisms are strongly associated with warfarin maintenance dosage requirements, supporting the potential clinical utility of pharmacogenomic-guided dosing.
No takes yet. Share an insight, caveat, or question.
VKORC1 variants may inform warfarin dosing in European-Americans; extends prior associations but leaves open outcome benefits in prospective trials.
T Li (2006) conducted an observational in Patients receiving anticoagulation (n=93). VKORC1 and CYP2C9 single nucleotide polymorphisms vs. Different genotypes was evaluated on Average weekly warfarin dose required to maintain patients at their desired anticoagulation target (p=<0.0001). VKORC1 single nucleotide polymorphisms were strongly associated with the average weekly warfarin dose required to achieve target INR (P<0.0001), with mean doses ranging from 27 to 47 mg by genotype.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: